Has Matthew Bassett, PA received payments from drug or device companies?

Yes. Drug and device makers reported $7,148 in general payments to Matthew Bassett, PA across 426 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Matthew Bassett, PA did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Matthew Bassett, PA come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Matthew Bassett, PA

Physician Assistant · Slidell, LANPI 1679909873

Payments from drug & device makers

$7,148in general payments, 2019–2025

Across 426 payments — averaging $16.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

GSK$2K
Novo Nordisk$831
AbbVie$506
Pfizer$419
AstraZeneca$409
Lilly USA, LLC$303
plus $3K from 39 others

What the payments were for

Food & beverage$7,08299%
Education$661%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
GSK	95	$1,551
Novo Nordisk	65	$831
AbbVie	37	$506
Pfizer	24	$419
AstraZeneca	12	$409
Lilly USA, LLC	20	$303
Astellas Pharma US Inc	12	$237
Exact Sciences	13	$232
Novartis	13	$224
Amgen	14	$215
E.r. Squibb & Sons, L.L.C.	12	$195
Ironwood Pharmaceuticals, Inc	11	$182
Bayer	11	$174
Merck	11	$171
Dexcom, Inc.	6	$152
Boehringer Ingelheim	8	$139
Sumitomo Pharma America, Inc.	6	$117
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	7	$115
Jazz Pharmaceuticals Inc.	2	$101
Mannkind Corporation	1	$90
Nestle Healthcare Nutrition Inc.	1	$86
Johnson & Johnson	5	$72
Sanofi-aventis U.S. LLC	5	$67
Phathom Pharmaceuticals, Inc.	3	$50
Amneal Pharmaceuticals LLC	3	$48
Saluda Medical Americas, Inc.	1	$42
Abbott	3	$41
Otsuka America Pharmaceutical, Inc.	2	$33
Paratek Pharmaceuticals, Inc.	2	$31
Alfasigma USA, Inc.	2	$30
Almatica Pharma LLC	2	$30
Kowa Pharmaceuticals America, Inc.	2	$29
Eisai Inc.	2	$26
Takeda Pharmaceuticals U.S.A., Inc.	2	$24
Edwards Lifesciences	1	$22
Amarin Pharma, Inc.	1	$20
Supernus Pharmaceuticals, Inc.	1	$20
Corcept Therapeutics	1	$19
Genentech USA, Inc.	1	$17
Ultragenyx Pharmaceutical Inc.	1	$16
IBSA Pharma Inc.	1	$14
Vertex	1	$14
Biohaven Pharmaceutical Holding Company Ltd.	1	$13
Phadia US Inc.	1	$11
Esperion Therapeutics, Inc.	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

BREZTRI$125
AREXVY$125

How this compares

$7,148 in reported general payments places this provider in the 95th percentile of 1,246 physician assistant providers in Louisiana.

See all physician assistant providers in Louisiana →

Medicare billing

Part B allowed, 2024

$52,066

Medicare patients

222

Services billed

689

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OzempicSemaglutide	105	$124,117
JardianceEmpagliflozin	88	$93,067
EliquisApixaban	75	$78,748
MounjaroTirzepatide	50	$60,045
XareltoRivaroxaban	40	$42,978
Trelegy ElliptaFluticasone/Umeclidin/Vilanter	40	$41,925
TrulicityDulaglutide	24	$25,597
LinzessLinaclotide	23	$23,728
FarxigaDapagliflozin Propanediol	28	$23,475
Soliqua 100-33Insulin Glargine/Lixisenatide	13	$22,397
RybelsusSemaglutide	17	$16,346
MyrbetriqMirabegron	13	$13,107
JanuviaSitagliptin Phosphate	12	$12,649
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog	15	$11,319
Tresiba Flextouch U-100Insulin Degludec	18	$10,086

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Novo NordiskOzempic, Rybelsus	$831	$140,463122 claims
Boehringer IngelheimJardiance	$139	$93,06788 claims
Lilly USA, LLCMounjaro, Trulicity	$303	$85,64274 claims
PfizerEliquis	$419	$78,74875 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta	$1,551	$55,60065 claims
Johnson & JohnsonXarelto	$72	$42,97840 claims
AstraZenecaFarxiga, Symbicort	$409	$31,27548 claims
AbbVieLinzess, Synthroid	$506	$26,99459 claims
Sanofi-aventis U.S. LLCSoliqua 100-33	$67	$22,39713 claims
Astellas Pharma US IncMyrbetriq	$237	$13,10713 claims
MerckJanuvia	$171	$12,64912 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium	$48	$2,985293 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,246 physician assistant providers in Louisiana.